Preclinical discovery reveals novel tetrahydropyridinyl-6,6-bicyclic 5-HT2A agonists, indicating therapeutic potential for depression, anxiety, substance abuse, and headaches.
Provided herein are novel tetrahydropyridinyl-6,6-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.
No takes yet. Share an insight, caveat, or question.
Sabnis et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: